Compounds > psychollatine
Page last updated: 2024-11-13

psychollatine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

psychollatine: from Psychotria umbellata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46878353
CHEMBL ID606760
MeSH IDM0483543

Synonyms (2)

Synonym
CHEMBL606760
psychollatine

Research Excerpts

Overview

Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell.

ExcerptReferenceRelevance
"Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell. "( Antioxidant and antimutagenic properties of the monoterpene indole alkaloid psychollatine and the crude foliar extract of Psychotria umbellata Vell.
do Nascimento, NC; e Silva, AC; Fett-Neto, AG; Fragoso, V; Moura, DJ; Richter, MF; Saffi, J, 2008)		2.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID380146Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 50 mg/kg, ip administered 30 mins prior to NMDA challenge2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377507Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378495Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 100 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377501Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378494Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377481Effect on locomotory activity in CF1 mouse assessed as reduction in spontaneous activity at 100 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380148Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 100 mg/kg, ip administered 30 mins prior to NMDA challenge2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377491Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 3 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378498Anxiolytic activity against CF1 mouse assessed as reduction in number in head dips at 200 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380150Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 7.5 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377492Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 7.5 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380155Decrease in spontaneous locomotor activity in mouse at 100 mg/kg2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377493Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 10 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378499Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380159Protective effect against amphetamine-induced lethality in mouse at 100 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID380151Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 10 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID378506Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 15 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378500Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377477Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 100 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380147Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 75 mg/kg, ip administered 30 mins prior to NMDA challenge2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID378505Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 15 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380157Protective effect against amphetamine-induced lethality in mouse at 10 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377494Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 30 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378509Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 3 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377478Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 2 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380154Decrease in spontaneous locomotor activity in mouse at 10 mg/kg2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID380161Inhibition of apomorphine-induced climbing behavior in mouse at 10 mg/kg, ip administered 30 mins prior to apomorphine challenge2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377466Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377499Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 0.85 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377495Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 100 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377484Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions for 60 mins2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378497Anxiolytic activity against CF1 mouse assessed as reduction in number in crossings at 200 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377467Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377479Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 3 to 30 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377486Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 7.5 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380153Decrease in spontaneous locomotor activity in mouse at 7.5 mg/kg2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377480Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 0.75 and 0.85 mg/kg2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377487Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 10 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378501Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377476Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg in presence of ritanserin for 5 mins2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380152Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 100 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377471Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg for 5 mins2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380158Protective effect against amphetamine-induced lethality in mouse at 30 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377498Effect on short term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377506Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 7.5 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378508Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 30 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377468Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377485Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 3 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377472Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg for 5 mins2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377475Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg in presence of ritanserin for 5 mins2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378507Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 15 mg/kg after 30 mins by hole-board assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377502Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 10 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377503Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 30 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380156Protective effect against amphetamine-induced lethality in mouse at 3 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		2.0310organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		2.0310primary amine
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.43201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		2.0210(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		2.0210dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		2.0210barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.0310aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
paraquat
Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.		2.0410organic cationgeroprotector;
herbicide
dizocilpine
[no description available]		2.0210secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
glycosides
[no description available]		3.1450
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		2.0310maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
scopolamine hydrobromide
[no description available]		2.0210
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		2.0410nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials